| Drug Name |
Zolmitriptan |
| Drug ID |
BADD_D02393 |
| Description |
Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797]
Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978] |
| Indications and Usage |
For the acute treatment of adult migraine with or without auras. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N02CC03 |
| DrugBank ID |
DB00315
|
| KEGG ID |
D00415
|
| MeSH ID |
C089750
|
| PubChem ID |
60857
|
| TTD Drug ID |
D0NG7O
|
| NDC Product Code |
69097-863; 68382-715; 69097-864; 64896-671; 54864-955; 64896-681; 65862-915; 64896-691; 68462-497; 68382-717; 64980-203; 11722-012; 59746-462; 50742-625; 55700-944; 46708-182; 55111-800; 63548-0101; 59746-433; 64896-672; 46708-181; 65862-914; 63850-4322; 63548-0102; 68001-250; 55700-943; 16571-804; 65841-768; 68382-712; 27241-022; 45802-711; 16571-803; 46708-462; 46708-463; 68001-249; 59746-461; 64980-257; 65862-801; 67835-5007; 64896-692; 64896-682; 65977-0050; 65841-766; 69238-2006; 68462-500; 71626-102; 64980-204; 71626-101; 50742-626; 65841-767; 68462-498; 65841-765; 72606-568; 64980-256; 68382-714; 72606-567; 68462-499; 65015-688; 69238-2007; 59746-432; 66039-845; 64567-0016; 46708-898; 65372-1145; 27241-021 |
| Synonyms |
zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol |
